In vivo studies validating multitargeting of prostanoid receptors for achieving superior anti‐inflammatory effects

@article{Woodward2017InVS,
  title={In vivo studies validating multitargeting of prostanoid receptors for achieving superior anti‐inflammatory effects},
  author={D. Woodward and J. Wang and Ming Ni and Alex Bauer and J. Martos and R. W. Carling and N. Poloso},
  journal={The FASEB Journal},
  year={2017},
  volume={31},
  pages={368 - 375}
}
  • D. Woodward, J. Wang, +4 authors N. Poloso
  • Published 2017
  • Biology, Medicine
  • The FASEB Journal
  • The purpose of these studies was to test the hypothesis that a selected polypharmacological approach for treating the prostanoid‐mediated component of inflammatory diseases would produce a therapeutic effect superior to global inhibition of prostaglandin (PG) biosynthesis by aspirin‐like drugs. The compound studied was AGN 211377, which had been previously shown to produce a superior effect on cytokine release from human macrophages compared with cyclooxygenase (COX) inhibitors. AGN 211377… CONTINUE READING
    3 Citations
    Role of the PGE2 receptor in ischemia-reperfusion injury of the rat retina
    • 1
    • PDF
    Lipid Signaling in Ocular Neovascularization
    • 1
    • PDF

    References

    SHOWING 1-10 OF 58 REFERENCES
    Multitargeting of selected prostanoid receptors provides agents with enhanced anti‐inflammatory activity in macrophages
    • J. Wang, D. Woodward, +4 authors L. Marnett
    • Medicine, Biology
    • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
    • 2016
    • 6
    Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor.
    • 50
    Cyclooxygenase 2 is a key enzyme for inflammatory cytokine‐induced angiogenesis
    • T. Kuwano, S. Nakao, +4 authors M. Ono
    • Biology, Medicine
    • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
    • 2004
    • 250
    The classification of prostaglandin DP‐receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist
    • 177
    International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress
    • 327
    • PDF
    In vitro and in vivo characterization of PF‐04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist
    • 101
    • Highly Influential
    The role of PGE2 receptor EP4 in pathologic ocular angiogenesis.
    • 66
    • PDF
    Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist.
    • 337